PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 9005120

[Imaging methods, particularly magnetic resonance, in multiple sclerosis].

Z Seidl·J Obenberger
View original source ↗Export metadata ↓

Abstract

Multiple sclerosis (MS) can only be diagnosed with a certain probability. There are neither any specific moments in the medical history of the patient, nor clinical or paraclinical tests as well as their combinations that would prove the diagnosis. In the daily routine the most common criteria we use are of Schumacher, Poser and Bartel. Until the magnetic resonance imaging (MRI) had been introduced into the clinical practice, imaging methods were used to exclude other treatable lesions (e.g. tumors, arteriovenous malformations etc.), even though computerized tomography (CT) successfully demonstrated some of the plaques. In the MS CT is both insufficiently sensitive as well as specific. On the contrary MRI is in the MS highly sensitive, 92-98% specificity has been achieved among clinical definite cases. MR is nowadays a method of choice for not only the diagnosis but also for the further follow up of our MS patients. Multiple focal hyperintense lesions on T2 weighted images (T2WI) or the flow attenuated inversion recovery imaging mode (FLAIR) are the typical pathological findings.

Explore related subjects

BrainDiagnosis, DifferentialMagnetic Resonance ImagingMultiple SclerosisTomography, X-Ray ComputedJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Z Seidl, J Obenberger. 1996-12-04. [Imaging methods, particularly magnetic resonance, in multiple sclerosis].. https://pubmed.ncbi.nlm.nih.gov/9005120/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2026

A MAGIBU-based model for pediatric and juvenile CNS tumors: an in-house epigenetic decision-support framework compared with online DNA methylation classifiers.

Background: DNA methylation profiling is a tool that provides key support for central nervous system (CNS) tumor classification. However, diagnostically ambiguous pediatric cases may result in discordant outputs across classifiers. We developed MAGIBU, a cross-platform, projection-based framework that embeds individual methylomes into a fixed CNS reference landscape, ranking diagnostic entities by local epigenetic proximity to support clinician-led integrative diagnosis. Methods: As a proof-of-concept, we evaluated MAGIBU in eight morphologically challenging pediatric/juvenile CNS tumors with unresolved diagnoses after institutional and central pathology review. To establish a benchmark in the absence of a definitive histopathological ground truth, a consensus epigenetic reference was defined a priori for cases showing concordant results between the Heidelberg CNS Tumor Methylation Classifier and Methylscape Analysis. Comparisons were also performed with Epigenomic Digital Pathology (EpiDiP). To validate MAGIBU beyond this discovery cohort, performance was assessed at the family level across the CNS methylation spectrum (n = 678, 28 methylation families), on non-array platforms (whole-genome bisulfite sequencing and Oxford Nanopore), and in a focused analysis of the low-grade glioma and diffuse midline glioma compartment across four independent cohorts (n = 670). Results: In the discovery cohort, MAGIBU achieved high concordance with the consensus reference (Cohen's κ = 0.855), outperforming EpiDiP (κ = 0.278), which frequently placed low-grade tumors in proximity to higher-grade reference regions. Conclusions: MAGIBU provides a stable, quantitative differential diagnosis framework that mitigates the limitations of rigid categorical assignments. By leveraging a distance-based proximity metric, it offers a transparent decision-support tool that integrates effectively with clinical, radiological, and molecular data. While performance is inherently dependent on reference atlas composition, MAGIBU represents a robust complementary approach for the diagnostic workup of ambiguous CNS tumors.

Brain↗
PubMed2021

1q21.1 distal copy number variants are associated with cerebral and cognitive alterations in humans.

Low-frequency 1q21.1 distal deletion and duplication copy number variant (CNV) carriers are predisposed to multiple neurodevelopmental disorders, including schizophrenia, autism and intellectual disability. Human carriers display a high prevalence of micro- and macrocephaly in deletion and duplication carriers, respectively. The underlying brain structural diversity remains largely unknown. We systematically called CNVs in 38 cohorts from the large-scale ENIGMA-CNV collaboration and the UK Biobank and identified 28 1q21.1 distal deletion and 22 duplication carriers and 37,088 non-carriers (48% male) derived from 15 distinct magnetic resonance imaging scanner sites. With standardized methods, we compared subcortical and cortical brain measures (all) and cognitive performance (UK Biobank only) between carrier groups also testing for mediation of brain structure on cognition. We identified positive dosage effects of copy number on intracranial volume (ICV) and total cortical surface area, with the largest effects in frontal and cingulate cortices, and negative dosage effects on caudate and hippocampal volumes. The carriers displayed distinct cognitive deficit profiles in cognitive tasks from the UK Biobank with intermediate decreases in duplication carriers and somewhat larger in deletion carriers-the latter potentially mediated by ICV or cortical surface area. These results shed light on pathobiological mechanisms of neurodevelopmental disorders, by demonstrating gene dose effect on specific brain structures and effect on cognitive function.

Brain↗